Alcon Inc. Stock News

STAAR Surgical Co. NASDAQ: STAA develops and manufactures intraocular lenses (IOL) used to replace a person's natural lenses during cataract surgery. Its portfolio includes the EVO line of Implantable

Strength in the Surgical and Vision Care businesses bodes well for Alcon (ALC).

Alcon's (ALC) Clareon platform is available in India in two PCIOL technologies, PanOptix and Vivity.

Alcon's (ALC) Vivity features the first-of-its-kind, patented wavefront-shaping technology, which simplifies presbyopia correction for surgeons and patients.

Alcon, Inc. (ALC) Q4 2023 Earnings Call Transcript

Alcon (ALC) delivers impressive performance across its franchises in the fourth quarter of 2023.

Although the revenue and EPS for Alcon (ALC) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street

In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.

Beyond analysts' top -and-bottom-line estimates for Alcon (ALC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter en

In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.

Investors with an interest in Medical - Instruments stocks have likely encountered both Alcon (ALC) and Idexx Laboratories (IDXX). But which of these two stocks presents investors with the better valu

Alcon (ALC) Q3 revenues increase year over year, driven by strength in Surgical and Vision Care segments.

While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare

Alcon Inc. shares ALC, +4.04% dropped more than 4% premarket on Wednesday after the eye care company on Tuesday reported third-quarter revenues below analysts' expectations.

Investors continue to be optimistic about Alcon (ALC), backed by a competitive product portfolio and strong commercial execution.